Special Issue

The Role of SOX Transcription Factors in Cancer

Message from the Guest Editors

SOX transcription factors contain a high mobility group (HMG) domain, a conserved amino acid sequence that was originally identified in Sry, a transcription factor that is essential for male sex determination. The SOX family comprises more than 20 members and is recognized as a key element in the development of many organs. It is now clear that SOX proteins also play important roles in the development of many human cancers. Some SOX are oncogenes, others are tumor suppressors, and others can be either oncogenes or tumor suppressors depending on the context. In this Special Issue of Cancers, we intend to highlight the complex, paradoxical, and fascinating roles of SOX in several types of cancer. We aim to cover both fundamental and clinical aspects of this field in order to provide an overview of the mechanisms of action of SOX transcription factors and their clinical potential in the management of human cancers.

Guest Editors

Dr. Philippe Blache

Institut de Recherche en Cancérologie de Montpellier (IRCM), University of Montpellier, ICM, INSERM U1194, Montpellier, France

Dr. Corinne Prévostel

Institut de Recherche en Cancérologie de Montpellier (IRCM), University of Montpellier, ICM, INSERM U1194, Montpellier, France

Deadline for manuscript submissions

closed (30 September 2021)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/51511

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com_

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, LISA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

